PTGER1, prostaglandin E receptor 1, 5731

N. diseases: 44; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.330 AlteredExpression group BEFREE Here we investigated (a) the expression profile of the PGE synthase enzymes (PTGES, PTGES-2, PTGES-3) and PGE receptors (PTGER1-4) in endometrial adenocarcinomas compared with normal endometrium and (b) the role of PTGER4 in endometrial tumorigenesis in vivo. 21589857 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.330 AlteredExpression group BEFREE Moreover, immunohistochemical analysis using serial sections of human colon adenocarcinomas revealed a strong positive correlation between COX-2 and FasL (r=0.722; P<0.0001) expression, and between EP1 receptor and FasL (r=0.740; P<0.0001) expression, in the tumour cells. 18648368 2008
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.330 AlteredExpression group LHGDN Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. 14744769 2004
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.330 Biomarker group CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.310 GeneticVariation phenotype BEFREE The effects of the COX-2 inhibitor, parecoxib (intraperitoneal 10 mg kg<sup>-1</sup>), or the EP-1R antagonist, SC51089 (intraperitoneal 100 μg kg<sup>-1</sup>), on hyperalgesia and spinal PGE2 were examined. 29576123 2018
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.310 Biomarker phenotype CTD_human These results demonstrate that spinal EP1 receptors are involved in the PGE2-induced allodynia and that spinal EP3 receptors are involved in the hyperalgesia induced by low doses of PGE2. 11375261 2001
CUI: C0020295
Disease: Hydronephrosis
Hydronephrosis 		0.300 Biomarker disease CTD_human The role of prostaglandin E2 receptor EP1 in 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced neonatal hydronephrosis in mice. 30641090 2019
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.300 Biomarker disease CTD_human The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors. 21739481 2012
CUI: C0237873
Disease: Physiological Sexual Disorders
Physiological Sexual Disorders 		0.300 Therapeutic phenotype CTD_human Identification of prostaglandin E2 receptors mediating perinatal masculinization of adult sex behavior and neuroanatomical correlates. 18726914 2008
CUI: C0021367
Disease: Mammary Ductal Carcinoma
Mammary Ductal Carcinoma 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0024667
Disease: Animal Mammary Neoplasms
Animal Mammary Neoplasms 		0.300 Biomarker phenotype CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0024668
Disease: Mammary Neoplasms, Experimental
Mammary Neoplasms, Experimental 		0.300 Biomarker phenotype CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0205641
Disease: Adenocarcinoma, Basal Cell
Adenocarcinoma, Basal Cell 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0205642
Disease: Adenocarcinoma, Oxyphilic
Adenocarcinoma, Oxyphilic 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0205643
Disease: Carcinoma, Cribriform
Carcinoma, Cribriform 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0205644
Disease: Carcinoma, Granular Cell
Carcinoma, Granular Cell 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0205645
Disease: Adenocarcinoma, Tubular
Adenocarcinoma, Tubular 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C0458247
Disease: Allodynia
Allodynia 		0.300 Biomarker phenotype CTD_human Activation of EP1 receptors appears to be upstream, rather than downstream, of NMDA receptor activation and NO production in the PGE2-induced allodynia. 11375261 2001
CUI: C0751211
Disease: Hyperalgesia, Primary
Hyperalgesia, Primary 		0.300 Biomarker phenotype CTD_human Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. 11375261 2001
CUI: C0751212
Disease: Hyperalgesia, Secondary
Hyperalgesia, Secondary 		0.300 Biomarker phenotype CTD_human Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. 11375261 2001
CUI: C0751213
Disease: Tactile Allodynia
Tactile Allodynia 		0.300 Biomarker phenotype CTD_human Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. 11375261 2001
CUI: C0751214
Disease: Hyperalgesia, Thermal
Hyperalgesia, Thermal 		0.300 Biomarker phenotype CTD_human Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. 11375261 2001
CUI: C1134719
Disease: Invasive Ductal Breast Carcinoma
Invasive Ductal Breast Carcinoma 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C1257925
Disease: Mammary Carcinoma, Animal
Mammary Carcinoma, Animal 		0.300 Biomarker disease CTD_human Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. 11751431 2001
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.300 Biomarker phenotype CTD_human Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. 11375261 2001